Apigenin (Synonyms: 芹菜素; 4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1)

目录号: HY-N1201 纯度: 99.58%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Apigenin (4',5,7-Trihydroxyflavone) 是一种竞争性 CYP2C9 抑制剂，K_i 为 2 μM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Apigenin Chemical Structure

CAS No. : 520-36-5

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥500	In-stock
50 mg	￥570	In-stock
100 mg	￥980	In-stock
200 mg	￥1475	In-stock
500 mg	￥2400	In-stock
1 g		询价
5 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Apigenin:

MCE 顾客使用本产品发表的 25 篇科研文献

: Apigenin purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2018 Oct 29;37(1):261. [Abstract]; A375 cells are incubated with DMSO, curcumin (25 μM), or apigenin (30 μM) for 4 h and then treated with IFN-γ (10 ng/mL) for indicated times. The levels of STAT1 phosphorylation at Tyr701 and total STAT1 are detected by Western blot analysis.

: Apigenin purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2018 Oct 29;37(1):261. [Abstract]; Western analysis of PD-L1 expression in A375, A2058, and RPMI-7951 cells treated with IFN-γ, curcumin, or apigenin.

: Apigenin purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2018 Oct 29;37(1):261. [Abstract]; A375 cells are incubated with DMSO, curcumin (25 μM), or apigenin (30 μM) for 4 h and then treated with IFN-γ (10 ng/mL) for indicated times. The levels of STAT1 phosphorylation at Tyr701 and total STAT1 are detected by Western blot analysis.

: Apigenin purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2018 Oct 29;37(1):261. [Abstract]; The protein expression levels of cleaved PARP are detected from Curcumin and Apigenin-treated A375, A2058, and RPMI-7951 cell lysates compared to control samples using Western blotting analyses.

: Apigenin purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2018 Oct 29;37(1):261. [Abstract]; A375, A2058, and RPMI-7951 cells were treated with DMSO (control), Curcumin (25 μM), or Apigenin (30 μM) for 24 h. Apigenin and Curcumin induce apoptosis in melanoma cells.

: Apigenin purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2018 Oct 29;37(1):261. [Abstract]; A375 cells are incubated with DMSO, curcumin (25 μM), or apigenin (30 μM) for 4 h and then treated with IFN-γ (10 ng/mL) for indicated times. The levels of STAT1 phosphorylation at Tyr701 and total STAT1 are detected by Western blot analysis.

Apigenin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Cytochrome P450 亚型特异性产品:

查看所有亚型

CYP1 CYP2 CYP3 CYP4 CYP11 CYP17 Aromatase/CYP19A1 CYP26 CYP51 CYP1A2 CYP2D6 CYP2C9 CYP2C19 CYP3A4 CYP17A1

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Apigenin (4',5,7-Trihydroxyflavone) is a competitive CYP2C9 inhibitor with a K_i of 2 μM.

IC₅₀ & Target

CYP2

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	EC₅₀	101 μM Compound: 6	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 12027739]
B16-BL6	EC₅₀	31.6 μM Compound: 6	Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 12027739]
BALB/3T3	IC₅₀	141.4 μM Compound: 4	Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay	[PMID: 10096863]
C2C12	IC₅₀	26.58 μg/mL Compound: 4	Cytotoxicity against mouse C2C12 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse C2C12 cells assessed as reduction in cell viability by MTT assay	[PMID: 33412152]
C8166	CC₅₀	17.2 μg/mL Compound: 4	Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24794743]
C8166	EC₅₀	4.46 μg/mL Compound: 4	Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis	[PMID: 24794743]
H9	IC₅₀	35 μM Compound: 12	Cytotoxicity against human H9 cells after 3 days Cytotoxicity against human H9 cells after 3 days	[PMID: 8158164]
H9	EC₅₀	9 μM Compound: 12	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay	[PMID: 8158164]
HCT-116	EC₅₀	23.8 μM Compound: Apigenin	Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26529431]
HEK293	IC₅₀	> 10 μM Compound: 24	Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay	[PMID: 30943030]
HEK293	IC₅₀	1.13 μM Compound: 7g	Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay	[PMID: 20731357]
HEK293	EC₅₀	24.9 μM Compound: 15	Agonist activity at mouse PPARgamma expressed in HEK293 cells co-expressing with Gal4 reporter vector after 24 hrs by dual-luciferase reporter assay Agonist activity at mouse PPARgamma expressed in HEK293 cells co-expressing with Gal4 reporter vector after 24 hrs by dual-luciferase reporter assay	[PMID: 24955889]
HeLa	IC₅₀	≥ 10 μM Compound: apigenin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 19278239]
HeLa	IC₅₀	21.3 μM Compound: 8	Antiproliferative activity against human HeLa cells after 48 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 48 hrs by CCK8 assay	[PMID: 29475587]
HeLa	EC₅₀	92.7 μM Compound: 6	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 12027739]
HeLa S3	IC₅₀	> 10 μM Compound: 9	Cytotoxicity against human HeLa S3 cells assessed as cell viability incubated for 48 hrs by microscopic analysis Cytotoxicity against human HeLa S3 cells assessed as cell viability incubated for 48 hrs by microscopic analysis	[PMID: 35704432]
HepG2	IC₅₀	70.18 μM Compound: Apigenin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26896708]
HL-60	IC₅₀	22.3 μM Compound: 8	Antiproliferative activity against human HL60 cells after 48 hrs by CCK8 assay Antiproliferative activity against human HL60 cells after 48 hrs by CCK8 assay	[PMID: 29475587]
HT-1080	EC₅₀	36.6 μM Compound: 6	Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 12027739]
HT-22	EC₅₀	> 100 μM Compound: 10	Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay	[PMID: 32991171]
Huh-7	CC₅₀	> 50 μM Compound: 21	Cytotoxicity against human Huh7.5.1 cells by MTT assay Cytotoxicity against human Huh7.5.1 cells by MTT assay	[PMID: 22445328]
Huh-7	EC₅₀	12 μM Compound: 21	Antiviral activity against HCV genotype 2a J399LM in Human Huh7.5.1 replicon cells assessed as suppression of viral replication after 72 hrs by luciferase reporter gene assay Antiviral activity against HCV genotype 2a J399LM in Human Huh7.5.1 replicon cells assessed as suppression of viral replication after 72 hrs by luciferase reporter gene assay	[PMID: 22445328]
Huh-7	EC₅₀	7.9 μM Compound: 21	Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay	[PMID: 22445328]
Jurkat	IC₅₀	1 μM Compound: Apigenin	Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method	[PMID: 30776692]
Jurkat	IC₅₀	1.8 μM Compound: Apigenin	Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method	[PMID: 30776692]
L02	IC₅₀	> 100 μM Compound: Apigenin	Cytotoxicity against human LO2 cells after 48 hrs by MTT assay Cytotoxicity against human LO2 cells after 48 hrs by MTT assay	[PMID: 26896708]
L6	IC₅₀	18.1 μg/mL Compound: 16	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue staining based fluorescence analysis Cytotoxicity against rat L6 cells after 72 hrs by alamar blue staining based fluorescence analysis	10.1039/C5MD00481K
L6	IC₅₀	21.8 μg/mL Compound: 16	Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by photometric method Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by photometric method	10.1039/C5MD00481K
MCF7	IC₅₀	1 μM Compound: Apigenin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay	[PMID: 33257172]
MCF7	IC₅₀	5.9 μM Compound: 9	Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining	[PMID: 21354800]
MDCK	CC₅₀	> 300 μM Compound: 1	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 19729316]
MDCK	IC₅₀	3.1 μM Compound: 9	Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining	[PMID: 21354800]
MDCK	CC₅₀	39.59 μM Compound: 1	Cytotoxicity against MDCK cells by MTT assay Cytotoxicity against MDCK cells by MTT assay	[PMID: 18640042]
Monocyte	IC₅₀	1.2 μM Compound: apigenin	Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs	[PMID: 8882428]
Monocyte	IC₅₀	20 μM Compound: Apigenin	Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA	[PMID: 10096854]
MV4-11	GI₅₀	2.81 μM Compound: 2	Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay	[PMID: 23411073]
Neutrophil	IC₅₀	12.3 μM Compound: 4c	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	16.2 μM Compound: 4c	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	24 μM Compound: 4c	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	7.7 μM Compound: 4c	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay	[PMID: 23871908]
Peritoneal macrophage	IC₅₀	7.7 μM Compound: 2;kp16	Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method	[PMID: 27955927]
RAW264.7	IC₅₀	13.4 μM Compound: 12	Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as decrease in PGE2 production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 31747281]
RAW264.7	IC₅₀	14 μM Compound: 2;kp16	Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells measured after 16 hrs Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells measured after 16 hrs	[PMID: 27955927]
RAW264.7	IC₅₀	18.4 μM Compound: 18	Inhibition of LPS induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay Inhibition of LPS induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess reagent based assay	[PMID: 33667099]
RAW264.7	IC₅₀	6.7 μM Compound: 8	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs by Griess reagent method Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs by Griess reagent method	[PMID: 19778086]
RAW264.7	CC₅₀	65.1 μM Compound: 18	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 33667099]
RAW264.7	IC₅₀	7.7 μM Compound: Apigenin	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 24 hrs by Griess reagent Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 24 hrs by Griess reagent	[PMID: 20363145]
RBL-2H3	IC₅₀	124 μM Compound: 5	Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge	[PMID: 14510616]
RS4-11	GI₅₀	27.9 μM Compound: 2	Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay	[PMID: 23411073]
THP-1	IC₅₀	60 μM Compound: Apigenin	Cytotoxicity against human THP1 cells after 24 hrs by MTS assay Cytotoxicity against human THP1 cells after 24 hrs by MTS assay	[PMID: 19879672]

体外研究
(In Vitro)

Apigenin (4',5,7-Trihydroxyflavone) 抑制细胞色素 P450 2C9 (CYP2C9)，在 CYP2C9 RECO 系统 (一种含有重组人 CYP2C9、P450 的纯化重组酶系统) 中，K_i 为 2 μM还原酶、细胞色素 b₅ 和脂质体)^[1]。Apigenin 抑制细胞增殖。20、40、80 μM的 Apigenin 7d生长抑制率 (IR) 分别为38%、71%、99%。暴露于 Apigenin 24 或 48 小时后，SGC-7901 细胞的克隆形成以剂量和时间依赖性方式受到抑制。Apigenin 处理 24 和 48 h 后 80 μM 的克隆效率分别为 9.8% 和 5%，而对照组为 40.4% 和 43.4%^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Apigenin (4'，5，7-Trihydroxyflavone) 是一种天然类黄酮，具有广泛的生物学特性，包括抗氧化、抗炎、抗癌和神经保护作用。Apigenin (125 mg/kg 和 250 mg/kg) 减轻 Adriamycin (ADR) (24 mg/kg) 诱导的心肌损伤。Apigenin 抑制血清天冬氨酸氨基转移酶 (AST) 的释放。Apigenin 减少血清乳酸脱氢酶 (LDH) 的释放。Apigenin 降低血清肌酸激酶 (CK) 含量^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

270.24

Formula

C₁₅H₁₀O₅

CAS 号

520-36-5

性状

固体

颜色

Light yellow to green yellow

中文名称

芹菜素

结构分类

初始来源

微生物

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

溶解性数据

细胞实验：

DMSO 中的溶解度 : 83.33 mg/mL (308.36 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.7004 mL	18.5021 mL	37.0041 mL
5 mM	0.7401 mL	3.7004 mL	7.4008 mL
10 mM	0.3700 mL	1.8502 mL	3.7004 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.70 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.70 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： 0.5% CMC-Na/saline water
Solubility: 10 mg/mL (37.00 mM); 悬浊液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.58%

选择批次：

Data Sheet (646 KB) SDS (393 KB)

COA (296 KB) HNMR (117 KB) LCMS (96 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Si D, et al. Mechanism of CYP2C9 inhibition by flavones and flavonols. Drug Metab Dispos. 2009 Mar;37(3):629-34. [Content Brief]

[2]. Wu K, et al. Inhibitory effects of apigenin on the growth of gastric carcinoma SGC-7901 cells. World J Gastroenterol. 2005 Aug 7;11(29):4461-4. [Content Brief]

[3]. Yu W, et al. Apigenin Attenuates Adriamycin-Induced Cardiomyocyte Apoptosis via the PI3K/AKT/mTOR Pathway. Evid Based Complement Alternat Med. 2017;2017:2590676. [Content Brief]

Cell Assay ^[2]	The effect of Apigenin on the viability of cells is determined by MTT assay. Near-confluent stock cultures of human gastric cancer SGC-7901 cells are harvested with 0.2% EDTA and plated at a density of 2.5×10³/well in 96-well microtiter plates. After an overnight incubation to allow cell attachment, the medium is replaced by fresh medium containing different concentrations (0, 20, 40, and 80 μM) of Apigenin. Control wells receive DMSO (0.2%). Each concentration of Apigenin is repeated in four wells. After incubation for 24 h, one plate is assayed with a microplate reader at the wavelength of 570 nm. Before the assay, MTT (5 mg/mL in PBS) is added to each well and incubated for 4 h, then MTT solution is removed from the wells by aspiration. After careful removal of the medium, 0.1 mL of DMSO is added to each well, and the plate is shaken for 15 min. The data of 7 d are fed into the computer and the growth curve is drawn. The growth inhibition rate (IR) is calculated^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[3]	Mice^[3] Sixty healthy Kunming mice (26±2 g) are randomly assigned into two groups: a control group (n=15) and an ADR group (n=45). The ADR group is divided into three subgroups: ADR only without Apigenin (ADR, n=15), low-dose Apigenin (125 mg/kg/day, n=15), and high-dose Apigenin (250 mg/kg/day, n=15). All Apigenin-treated groups are treated daily via gastric gavage for seventeen days with a 125 or 250 mg/kg/day dose. ADR (3 mg/kg/day) is injected intraperitoneally into animals at an interval of 48 h (in total, eight times at a cumulative dose of 24 mg/kg). The mice in the control group receive injections of 0.9% sterile saline. On the 17th day after the first treatment, the mice are sacrificed, and blood samples are collected. A number of hearts are fixed with 2.5% glutaraldehyde fixative for electron microscopy analysis, and the others are stored at -80°C for western blot analysis. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Si D, et al. Mechanism of CYP2C9 inhibition by flavones and flavonols. Drug Metab Dispos. 2009 Mar;37(3):629-34. [Content Brief] [2]. Wu K, et al. Inhibitory effects of apigenin on the growth of gastric carcinoma SGC-7901 cells. World J Gastroenterol. 2005 Aug 7;11(29):4461-4. [Content Brief] [3]. Yu W, et al. Apigenin Attenuates Adriamycin-Induced Cardiomyocyte Apoptosis via the PI3K/AKT/mTOR Pathway. Evid Based Complement Alternat Med. 2017;2017:2590676. [Content Brief]

Apigenin 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.7004 mL	18.5021 mL	37.0041 mL	92.5104 mL
	5 mM	0.7401 mL	3.7004 mL	7.4008 mL	18.5021 mL
	10 mM	0.3700 mL	1.8502 mL	3.7004 mL	9.2510 mL
	15 mM	0.2467 mL	1.2335 mL	2.4669 mL	6.1674 mL
	20 mM	0.1850 mL	0.9251 mL	1.8502 mL	4.6255 mL
	25 mM	0.1480 mL	0.7401 mL	1.4802 mL	3.7004 mL
	30 mM	0.1233 mL	0.6167 mL	1.2335 mL	3.0837 mL
	40 mM	0.0925 mL	0.4626 mL	0.9251 mL	2.3128 mL
	50 mM	0.0740 mL	0.3700 mL	0.7401 mL	1.8502 mL
	60 mM	0.0617 mL	0.3084 mL	0.6167 mL	1.5418 mL
	80 mM	0.0463 mL	0.2313 mL	0.4626 mL	1.1564 mL
	100 mM	0.0370 mL	0.1850 mL	0.3700 mL	0.9251 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Apigenin520-36-54',5,7-Trihydroxyflavone Apigenol C.I. Natural Yellow 1芹菜素AutophagyCytochrome P450Endogenous MetaboliteCYPsInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Apigenin (Synonyms: 芹菜素; 4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1)

Customer Review

Other Forms of Apigenin:

MCE 顾客使用本产品发表的 25 篇科研文献

Apigenin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Cytochrome P450 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Apigenin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Apigenin (Synonyms: 芹菜素; 4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1)

Customer Review

Other Forms of Apigenin:

Apigenin 相关抗体

MCE 顾客使用本产品发表的 25 篇科研文献

Apigenin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Cytochrome P450 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Apigenin 相关抗体:

摩尔计算器

稀释计算器

Apigenin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z